SCHEMBL75936

SCHEMBL75936

CC(C)(C)OC(=O)N1CCC(Oc2ccc(OC(F)(F)C(F)F)cc2)CC1

nearest known ligand 0.59

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
GPR119 Q8TDV5 7/20 0.59
CHEK2 O96017 1/20 0.48
PDE4D Q08499 3/20 0.48
ALDH1A1 P00352 1/20 0.47
PDE4A P27815 2/20 0.47
PDE4B Q07343 2/20 0.47
PDE4C Q08493 2/20 0.47
PTPN2 P17706 1/20 0.46
PTPN1 P18031 1/20 0.46
PTPN6 P29350 1/20 0.46
HRH3 Q9Y5N1 1/20 0.46
MMP13 P45452 1/20 0.46
MMP14 P50281 1/20 0.46
KCNH2 Q12809 1/20 0.46
KDM1A O60341 1/20 0.46
USP30 Q70CQ3 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2951108 0.89 GPR119 (0.63) GPR119CHEK2ALDH1A1HRH3MMP13
SCHEMBL77291 0.87 GPR119 (0.60) GPR119CHEK2ALDH1A1HRH3MMP13
SCHEMBL23410111 0.85 GPR119 (0.61) GPR119CHEK2PDE4DALDH1A1PDE4A
SCHEMBL29981348 0.85 GPR119 (0.58) GPR119CHEK2ALDH1A1PDE4BHRH3
SCHEMBL23410126 0.85 GPR119 (0.58) GPR119CHEK2ALDH1A1PDE4BHRH3
SCHEMBL75039 0.84 GPR119 (0.58) GPR119CHEK2PDE4DPDE4APDE4B
SCHEMBL5538341 0.84 GPR119 (0.63) GPR119CHEK2ALDH1A1MMP13USP30
SCHEMBL3073527 0.84 GPR119 (0.65) GPR119CHEK2ALDH1A1HRH3MMP13
SCHEMBL2735422 0.82 GPR119 (0.67) GPR119CHEK2ALDH1A1HRH3USP30
SCHEMBL74203 0.82 GPR119 (0.67) GPR119CHEK2PDE4DALDH1A1PDE4A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8129412-B2 Hydantoin derivatives useful as metalloproteinase inhibitors ASTRAZENECA AB (SE) 2012-03-06 US disclosed
EP-1828166-B1 HYDANTOIN DERIVATIVES USEFUL AS METALLOPROTEINASE INHIBITORS ASTRAZENECA AB (SE) 2009-07-22 EP disclosed
US-20080280950-A1 Hydantoin Derivatives Useful as Metalloproteinase Inhibitors ASTRAZENECA AB (SE) 2008-11-13 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080280950-A1 Hydantoin Derivatives Useful as Metalloproteinase Inhibitors MMP3, MMP9, MMP2 GPR119 2077/4885CHEK2 4397/4885PDE4D 563/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.